Worth reading
—
Scored from 0 of 4 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Resolutions for the General Meeting of Shareholders
Director nominee3 new directors (6 outside directors scheduled to retire)
| Item | Details |
|---|---|
| Director nominee | 3 new directors (6 outside directors scheduled to retire) |
Items this document does not state (5)
Type of shareholders' meetingDate and timeMatters for resolutionShareholder ProposalPercentage voting in favor
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To prepare for the launch of multiple drug candidates, advance the late-stage development pipeline, introduce advanced technologies, address the adverse impact of mature products and accelerate future growth.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.